Disclaimer:
This news is brought to you by our author who has researched this information from the official website of AMA (American Medical Association). These facts and data is neither personal nor commercial study performed by Medical Billing Benefits.
The American Medical Association (AMA) on November 10, 2020, has unveiled new CPT codes for reporting COVID-19 vaccine products and immunization administration.
CPT’s editorial panel worked closely with the CDC and the CMS to create these codes. The code release includes two different vaccine products and two sets of unique administration codes—one for each vaccine.
As per details, these newly announced CPT codes will allow healthcare providers to report and track the administration of these COVID-19 vaccines. In addition to this, another major purpose of this early release is to aware the healthcare providers. So they can update their billing and medical record systems before the public availability of this vaccine. Moreover, these codes would be available after the approval of an emergency use authorization from the Food and Drug Administration.
The new vaccine codes are:
- 91300 (Pfizer): Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative-free, 30 mcg/0.3mL dosages, diluent reconstituted, for intramuscular use
Vaccine Manufacturer: Pfizer Inc
- 91301 (Moderna): Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative-free, 100 mcg/0.5mL dosages, for intramuscular use
Vaccine Manufacturer: Moderna Inc.
Each vaccine product code is linked with a pair of vaccine administration codes, which correspond to the first and second doses.
For the 91300 product code, The new vaccine administration CPT codes and long descriptions are:
- 0001A: immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative-free, 30 mcg/0.3 mL dosage, diluent reconstituted; the first dose
- 0002A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative-free, 30 mcg/0.3mL dosages, diluent reconstituted; second dose
For the 91301 product code, the administration codes are followed
- 0011A, immunization administration by intramuscular injection of SARS-CoV-2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative-free, 100 mcg/0.5 mL dosage; first dose
- 0012A, …Immunization administration by intramuscular injection of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative-free, 100 mcg/0.5mL dosages; second dose
In addition to this, healthcare providers can access short and medium descriptors for the new vaccine-specific CPT on the AMA website.
If your medical practice intends on providing these vaccines, you must start working with your billing and IT staff to plan for the addition of these codes. You can implement these codes in compliance with your respective billing and Electronic Medical Records (EMR) platforms. Moreover, in order to keep pace with the ever-changing healthcare industry, it is essential to train your medical billing and coding staff.
It’s worth mentioning here that the global COVID-19 pandemic has claimed approximately 1.3 million precious lives to date. And doctors all around the world are voicing hopes that vaccines could bring “herd immunity”.
Stay tuned with such latest news and information on Medical Billing Benefits. It is an advanced healthcare news wire. Subscribe to our Enewsletter to get the most recent information about the trends in medical billing and coding.